翰宇药业(300199) - 2025 Q1 - 季度业绩预告

Financial Performance - The company expects a net profit of 60 million to 72 million CNY for Q1 2025, a turnaround from a loss of 14.1 million CNY in the same period last year [3]. - Revenue is projected to be between 290 million and 310 million CNY, representing a growth of 93.00% to 106.31% compared to 150.26 million CNY in the previous year [3]. - The net profit attributable to shareholders is expected to increase by 74.1 million CNY to 86.1 million CNY compared to the same period last year [5]. Revenue Sources - The main revenue source for the company in this period is from overseas business, benefiting from sustained demand and high profit margins [6]. - The approval of liraglutide injection by the FDA on December 23, 2024, has led to the fulfillment of significant orders, contributing to revenue growth [6].